Pharmaceuticals
Dachser India receives IATA CEIV Pharma certification
MUMBAI, India, July 2, 2019 /PRNewswire/ -- The International Airport Transport Association (IATA) recently awarded theMumbai and Hyderabad branches of Dachser India with the prestigious CEIV Pharma certification, recognizing the company for its excellence in transporting Life Science and Healthc...
2019-07-02 17:12
2816
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Novel real world evidence for AFSTYLA® and IDELVION® to be highlighted MELBOURNE, Australia, July 2, 2019 /PRNewswire/ -- Global biotherapeutics leaderCSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation factor programs at this ...
2019-07-02 06:15
7912
Inaugural Winner of the Mundipharma Cancer Care Challenge Shines at Innovfest Unbound
SINGAPORE, June 28, 2019 /PRNewswire/ -- The five finalist teams of the inaugural 'Mundipharma Cancer Care Challenge' pitched their ideas on how to harness the power of technology to improve the lives of cancer patients to a panel of judges atSoutheast Asia's largest innovation festival, Innovfes...
2019-06-28 17:57
3475
Johnson & Johnson Innovation Opens JLABS @ Shanghai in Collaboration with Shanghai Pharma Engine Company Ltd.
SHANGHAI, June 27, 2019 /PRNewswire/ -- Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd., today announced the opening of JLABS @Shanghai, the world's largest JLABS and the first in Asia Pacific. The 4,400-square-meter facility, located inShanghai's Zhangjiang...
2019-06-27 19:13
11263
Yisheng Biopharma Receives IND Clearance from China NMPA to Initiate Clinical Trial of YS-ON-001 in the Treatment of Advanced Solid Tumors
BEIJING, June 27, 2019 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced that it has received Investigational New Drug (IND) cleara...
2019-06-27 09:00
2683
Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
PLYMOUTH MEETING, Pennsylvania, June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to tre...
2019-06-26 21:47
3350
Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres® Y-90 resin microspheres
Physicians and employees recognized for their role in this milestone and impact made on patient lives WOBURN, Massachusetts, June 24, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Sphe...
2019-06-24 21:00
2867
FDA Grants Orphan Drug Designation to XW Laboratories' XWL-008 for the Treatment of Patients with Narcolepsy
WUHAN, China, June 24, 2019 /PRNewswire/ -- XW Laboratories Inc. (XW Labs), a clinical-stage biopharmaceutical company pioneering the discovery of novel small molecule therapeutics for the treatment of neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has gr...
2019-06-24 17:00
3273
Singapore Health Sciences Authority Approves Vosevi(R) (Sofosbuvir/ Velpatasvir/ Voxilaprevir) for Re-treatment of Adults with Chronic Hepatitis C Virus
SINGAPORE, June 24, 2019 /PRNewswire/ -- Gilead Sciences, Inc. today announced that the Singapore Health Sciences Authority has approved Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), a once-daily single tablet regimen for the re-treatment of adults with genotype 1-6 chronic hepa...
2019-06-24 14:00
2333
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist
OSAKA, Japan, June 24, 2019 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi" or "the Company") announces that the Company has concluded an agreement with Eddingpharm(hereafter "Eddingpharm") to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name inJapan: MULPLETA® )...
2019-06-24 10:00
1949
European Medicines Agency Accepted First "China-Developed" Biosimilar - Henlius HLX02 Marketing Authorization Application for Review
* First China biosimilar conducted a multi-center, international phase 3 clinical trial * First trastuzumab developed in China following the National Medical Products Administration (NMPA) technical guideline for biosimilar with the New Drug Application (NDA) received the acceptance for revie...
2019-06-21 20:29
2637
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing
WUXI, China, June 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it planned to expand the new state-of-the-art ...
2019-06-21 08:39
3567
Gracell Data on Multi-center Investigation of FasT CAR-19 Therapy Shows Positive First Impact in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Preliminary data shows a high response rate, with 16 of 16 patients achieving complete remission and 14 of 16 patients achieving undetectable minimal residual disease with mild side effect observed - FasT CAR-19 (GC007F) can be manufactured overnight with 100% success - FasT CAR-19 is expecte...
2019-06-21 08:00
3468
Definiens & Targos Innovation: AI-powered multiplex IHC biomarker analytic solutions for precision medicine
Collaboration to bolster end-to-end services from assay development to confident informed clinical decision making MUNICH and KASSEL, Germany, June 20, 2019 /PRNewswire/ -- Definiens, a leading international Artificial Intelligence (AI)–based biomarker analysis and advanced data mining provider ...
2019-06-20 20:00
4678
dMed Biopharmaceutical, a next generation CRO, announced the opening of its US Regulatory Affairs office in Washington DC to build a bridge for affordable innovative drugs for US patients
WASHINGTON, June 19, 2019 /PRNewswire/ -- Since the China launch earlier this year of an immuno-oncology drug at one-third the price of Merck's Keytruda, there has been a wave of applications for affordable innovative therapies from China, developed to Western standards of safety and efficacy, ...
2019-06-19 23:59
3171
Piramal Pharma Solutions recognized by Frost & Sullivan for its End-to-End Integrated Services Across the Entire Drug Development Life Cycle
SANTA CLARA, California, June 18, 2019 /PRNewswire/ -- Based on its recent analysis of the contract development and manufacturing organization market, Frost & Sullivan recognized Piramal Pharma Solutions ('PPS', 'the business') with the 2019 Global Customer Service Leadership Award. Through its 1...
2019-06-18 20:00
1895
Seegene Establishes Brazilian Subsidiary
SEOUL, South Korea, June 18, 2019 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered inSouth Korea, announced today the formation of a new subsidiary, Seegene do Brasil Diagnosticos Ltda., inBelo Horizonte, Brazil. Seegene do Brasil Diagnos...
2019-06-18 19:00
2992
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings
SUZHOU, China, June 18, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the clinical results of CT103A, the potential best-in-class therapy of fully-human ...
2019-06-18 08:00
8057
China National Medical Products Administration Approves Sinovant's Clinical Trial Application for Lefamulin
- Chinese registrational clinical trial for lefamulin to begin in 2H 2019 BEIJING and SHANGHAI, June 14, 2019 /PRNewswire/ -- Sinovant Sciences today announced that its Clinical Trial Application (CTA) for lefamulin has been accepted by the Center for Drug Evaluation at the China National Medica...
2019-06-14 09:00
5825
Tessa Therapeutics and China-Singapore Guangzhou Knowledge City Form Landmark US$120 Million Joint Venture in China to Develop Innovative Cell Therapies for Cancer
* The partnership will leverage Tessa Therapeutics' global operational capabilities and cell therapy platform technologies to target prevalent cancers inChina * The joint venture will be the sole licensee of Tessa Therapeutics' cell therapies for research, development and commercialization in...
2019-06-13 07:15
2348
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 318 media titles]
2024-05-07 08:00
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
[Picked up by 316 media titles]
2024-05-08 14:37
OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology
[Picked up by 309 media titles]
2024-05-08 08:00IN2MF in Kuala Lumpur Presented by Bank Indonesia
[Picked up by 295 media titles]
2024-05-08 16:44
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
14849
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
10421
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
9809
